Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study

Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo-Controlled Study

(2016) Richard Weisler et al.   CNS SPECTRUMS

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

(2016) Robert M. Berman et al.   CNS SPECTRUMS

Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder

(2009) Michael Bauer et al.   JOURNAL OF CLINICAL PSYCHIATRY

Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder

(2009) Andrew J. Cutler et al.   JOURNAL OF CLINICAL PSYCHIATRY

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder

(2009) Ronald N. Marcus et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

P.2.g.008 Extended release quetiapine fumarate monotherapy as maintenance treatment in patients with major depressive disorder (MDD)

(2008) C. Datto et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

P.1.e.019 PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects

(2008) S. Nyberg et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel®

(2008) J.M. Goldstein et al.   EUROPEAN PSYCHIATRY